AXDX - Accelerate Diagnostics Inc Stock Price, Fair Value and News

$1.09+0.02 (+1.87%)

Delayed as of 26 Dec 2024, 11:04 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AXDX Price Action

Last 7 days

-7.0%

Last 30 days

-34.8%

Last 90 days

-36.7%

Trailing 12 Months

-75.3%

AXDX RSI Chart

AXDX Valuation

Market Cap

26.8M

Price/Earnings (Trailing)

-0.5

Price/Sales (Trailing)

2.25

EV/EBITDA

-0.14

Price/Free Cashflow

-1

AXDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AXDX Fundamentals

AXDX Revenue

Revenue (TTM)

11.9M

Rev. Growth (Yr)

-9.82%

Rev. Growth (Qtr)

-0.37%

AXDX Earnings

Earnings (TTM)

-53.5M

Earnings Growth (Yr)

-1.7K%

Earnings Growth (Qtr)

-26.33%

AXDX Profitability

EBT Margin

-444.13%

Return on Equity

110.26%

Return on Assets

-165.42%

Free Cashflow Yield

-100.22%

AXDX Investor Care

Shares Dilution (1Y)

72.12%

Diluted EPS (TTM)

-1.74

AXDX Alerts

1 major insider buys and 1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	12.2M	12.2M	11.9M	0
2023	12.6M	11.7M	12.0M	12.1M
2022	12.2M	13.3M	13.1M	12.8M
2021	11.3M	12.0M	11.5M	11.8M
2020	9.9M	10.2M	11.5M	11.2M
2019	6.6M	6.7M	7.6M	9.3M
2018	4.4M	5.4M	6.0M	5.7M
2017	613.0K	1.3M	2.1M	4.2M
2016	224.0K	226.0K	229.0K	246.0K
2015	122.0K	127.0K	132.0K	75.0K
2014	46.0K	52.0K	55.0K	122.0K
2013	80.0K	41.0K	48.2K	48.0K
2012	241.7K	238.8K	236.0K	158.0K
2011	0	0	244.5K	243.1K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Accelerate Diagnostics Inc

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.

CEO	Mr. Jack Phillips
WEBSITE	https://acceleratediagnostics.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	179

Accelerate Diagnostics Inc Frequently Asked Questions

What is the ticker symbol for Accelerate Diagnostics Inc? What does AXDX stand for in stocks?

AXDX is the stock ticker symbol of Accelerate Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Accelerate Diagnostics Inc (AXDX)?

As of Tue Dec 24 2024, market cap of Accelerate Diagnostics Inc is 26.8 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXDX stock?

You can check AXDX's fair value in chart for subscribers.

Is Accelerate Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether AXDX is over valued or under valued. Whether Accelerate Diagnostics Inc is cheap or expensive depends on the assumptions which impact Accelerate Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXDX.

What is Accelerate Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Dec 24 2024, AXDX's PE ratio (Price to Earnings) is -0.5 and Price to Sales (PS) ratio is 2.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXDX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Accelerate Diagnostics Inc's stock?

In the past 10 years, Accelerate Diagnostics Inc has provided -0.403 (multiply by 100 for percentage) rate of return.